Does Hawaii Med-QUEST Cover Wegovy or Zepbound? Not for Weight Loss

No. As of November 2026, Hawaii’s Med-QUEST Medicaid program will not pay for Wegovy, Zepbound or Saxenda when the goal is weight loss; AlohaCare, one of its health plans, states plainly that “drugs for weight loss” are not covered.^[1] Bills filed in the 2026 legislature describe the state as excluding these drugs “in most situations,” but no published Hawaii rule we could find says which situations qualify.^[2][3]

Does Hawaii Medicaid cover Wegovy for weight loss?

It does not. Under federal law, any state may leave weight-loss drugs out of Medicaid, and Hawaii does.^[4] AlohaCare’s QUEST page lists weight loss alongside erectile dysfunction, infertility and cosmetic uses as drug categories it will not cover.^[1] The same page says the plan covers every medically necessary drug that Med-QUEST covers, so the exclusion traces back to the state program, not one plan’s choice.^[1]

The 2026 bills confirm it from the other side. Both open with findings that the Department of Human Services has chosen to keep Saxenda, Wegovy and Zepbound out of Medicaid coverage in most situations.^[2][3] Our explainer on how Medicaid treats Ozempic and Wegovy covers the federal rule behind that choice.

What would the 2026 GLP-1 bills have changed?

House Bill 2456 and Senate Bill 3195 aimed to end the exclusion. Both would have made Medicaid members eligible for FDA-approved GLP-1s used for weight loss, prescribed by a practitioner, with no prior authorization.^[2][3] The House version, as amended in committee, dropped the original’s reference to Medicare Part D and added a condition that the patient take part in a lifestyle program supporting long-term weight maintenance.^[2][13]

Whether either bill moved further is not something we can state. The legislature’s document server holds only the introduced texts and the House committee draft, with no later Senate or conference draft for either, and the bill status pages could not be opened.^[2][3] The House bill named July 1, 2026 as its effective date; AlohaCare’s page, read four months after that date, still excludes weight-loss drugs.^[1][2] Any 2027 bill would start the process again.

Does Hawaii Medicaid cover Wegovy for heart disease or Zepbound for sleep apnea?

That is the open question. Wegovy is FDA-approved to lower the risk of heart attack and stroke in adults with heart disease and excess weight, and to treat the liver disease MASH; Zepbound carries approval for moderate to severe sleep apnea when obesity is also present.^[6][7] Many state Medicaid programs that exclude weight loss now cover one or more of those uses with prior authorization.

In Hawaii, the bills’ phrase “in most situations” suggests some uses are covered, but neither bill names them.^[2] We found no Med-QUEST or plan criteria for any of the three uses. One plan does treat Zepbound as a drug it reviews: ‘Ohana Health Plan’s QUEST Integration drug list update for September 1, 2026 tells pharmacies “PA Required. Use Zepbound KwikPen” and applies that pen rule “for all indications,” without saying which indications those are.^[14] AlohaCare’s exclusion is worded around weight loss, which leaves room for a request based on another diagnosis.^[1] A prescriber treating sleep apnea or established heart disease can file one and see how the plan rules. Our pages on Zepbound for sleep apnea and GLP-1s for MASH explain the evidence behind those approvals.

Can a teenager on QUEST get a GLP-1?

Wegovy and Saxenda are both approved for obesity from age 12, Saxenda only above 60 kg.^[6][8] Federal child-health rules, known as EPSDT, require Medicaid to provide necessary treatment for members under 21 whether or not the state plan covers it.^[5] We found no Hawaii document applying that rule to GLP-1s. A family can still ask the plan to review a request on that basis, with records showing why the drug is needed. Our review of GLP-1 drugs in teenagers covers what the trials found.

How do you ask for coverage or appeal in Hawaii?

Start with the plan. AlohaCare takes pharmacy prior authorization requests from prescribers at 808-973-7418 or 866-973-7418, by fax at 1-866-728-0233 or 1-877-252-5224, or electronically, which it prefers.^[1] Members of other QUEST plans should use the numbers on their own card.

Federal rules set the appeal clock for Medicaid health plans. A member has 60 days from a denial notice to appeal to the plan, and then at least 90 and at most 120 days from the plan’s decision to ask the state for a fair hearing.^[9][10] The notice gives the exact dates. Appeals stand on the strongest ground for a non-weight use with a documented diagnosis. Our walkthrough of prior authorization and appeals covers what to include, and the Hawaii state page collects the Medicaid basics.

What can you do if Med-QUEST won’t pay?

Self-pay is the fallback, since Lilly’s copay card terms exclude anyone enrolled in Medicaid.^[11] In the prices we track, Novo Nordisk sells most Wegovy pen doses for $349 a month to self-pay patients, and Lilly’s Zepbound runs from $299 at the starting dose to $449 at higher doses refilled on time.^[11][12] Check each program’s terms on government coverage before enrolling, and compare them in our list of the cheapest GLP-1 options without insurance.